Information  X 
Enter a valid email address

C4X Discovery Holdings PLC 1P (C4XD)

Related News

21-Nov-2018 09:53 AM

C4X Discovery trims annual losses as revenue swells

Drug company C4X Discovery said Wednesday annual losses before tax narrowed sharply as revenues swelled after it penned its first commercial deal during the year. For the 12 months ended 31 July, losses before tax narrowed to £2.53m from £8.4
12-Apr-2018 09:56 AM

C4XD losses widen; receives upfront payment from Indivior deal

C4X Discovery Holdings, a pioneering drug discovery company, reported Thursday a wider net loss of £3.7m in the half year to the end of January, from a loss of £3.0m the previous year. Investment in R&D was £3.4m, up £0.4m from t
29-Mar-2018 08:09 AM

C4X signs licensing agreement with Indivior for addiction programme worth up to $294m

C4X Discovery Holdings announced Thursday that it has signed a licensing agreement with Indivior to further develop and commercialise C4XD's addition programme (C4X3256) worth up to $294m. Under the terms of the agreement, C4XD will receive an upf
14-Dec-2017 07:20 AM

C4XD after-tax losses widen

C4X Discovery Holdings posts after-tax losses of £6,782,000 or 16.88p per share for the year to the end of July - up from £5,321,000 or 16.83p per share last time. Revenues - which fell to £143,000 from £279,000 - were largely ge
13-Nov-2017 09:54 AM

C4XD presentation on lead addiction programme:

C4X Discovery Holdings presented new pre-clinical data on its Orexin-1 antagonist programme at Neuroscience 2017 on 11 Nov in Washington, DC. C4XD's lead programme, Orexin-1, aims to treat addiction by targeting the 'craving' process itsel
05-Sep-2017 09:07 AM

C4X Discovery sees continued progress

C4X Discovery Holdings said it has continued to make progress towards its aim of becoming the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting
27-Apr-2017 09:28 AM

C4X Discovery revenues fall

C4X Discovery's pre-tax losses rose to £3.9m in the six months to the end of January - up from £3.4m last time. Revenues fell to £78,000 from £165,000 a year ago and operating losses rose to £3.9m from £3.5m. Chi
21-Feb-2017 08:00 AM

Broker Forecast - Panmure Gordon issues a broker note on C4x Discovery Holdings Plc

Panmure Gordon today initiates coverage of C4x Discovery Holdings Plc (LON:C4XD) with a buy investment rating and price target of 129p. Story provided by StockMarketWire.com...
09-Feb-2017 09:49 AM

C4XD appoints Nomad

C4X Discovery Holdings has appointed Panmure Gordon (UK) as the company's nominated adviser and broker with immediate effect. At 9:49am: (LON:C4XD) C4x Discovery Holdings Plc share price was +1p at 93.5p Story provided by StockMarketWire.com.
06-Jan-2017 07:35 AM

C4XD losses widen

C4X Discovery Holdings posts an after-tax loss of £5,321,000 or 16.83 pence per share for the year to the end of July - up from £3,064,000 or 10.77 pence per share in 2015. R&D expenses increased by 66% to £5,239,000 while administra
28-Sep-2016 07:28 AM

C4X in new collaboration with Evotec

C4X Discovery has entered into a multi-target, risk-sharing alliance with Evotec AG, a leading drug discovery alliance and development partnership company. The new agreement builds on the strategic collaboration between the two companies announced in Ja
04-Jul-2016 08:01 AM

C4XD identifies new drug targets for development

C4X Discovery Holdings has identified multiple new drug targets in the areas of inflammation and neurodegeneration. It says this represents the first major output from C4XD's proprietary genetic analysis platform, Taxonomy3, since it was acquired wi
17-Mar-2016 09:10 AM

C4XD operating losses rise

Innovative drug discovery and development company C4X Discovery Holdings posts an operating loss of GBP3.5m for the six months to the end of January - up from a restated GBP1.3m last time. Revenues fell to GBP165,000 from GBP173,000 and research and deve
01-Mar-2016 08:57 AM

C4X Discovery to present at the SHARES Investor Evening in Manchester on 10th March 2016

Clive Dix, Executive Chairman of C4X Discovery (C4XD) (LSE:C4XD) will be giving a briefing at the SHARES Investor Evening on 10th March 2016. It will take place in Manchester at an investor evening being organised by Shares Magazine; the event is supporte
01-Mar-2016 08:54 AM

C4XD acquires Adorial

C4X Discovery Holdings has acquired Adorial Limited together with its subsidiaries, a privately held drug discovery company with a proprietary genetic technology platform for the identification of novel drug targets. Adorial's key genetic technolog
08-Dec-2015 02:56 PM

C4X Discovery resolutions passed at AGM

C4X Discovery Holdings has confirmed that all resolution proposed at its annual general meeting yesterday were passed. At 2:56pm: (LON:C4XD) C4x Discovery Holdings Plc Ord 1p share price was 0p at 77p Story provided by StockMarketWire.com...
20-May-2015 09:10 AM

C4XD drug candidate for pre-clinical development

C4X Discovery Holdings has selected a drug candidate from its Orexin-1 programme to enter pre-clinical development prior to the initiation of clinical studies for the treatment of stress-related addictive disorders. C4XD says this represents a major miles
27-Apr-2015 08:33 AM

C4X Discovery net losses widen

C4X Discovery Holdings posts a net loss of £0.8m or 3.1 pence per share for the six months to the end of January - up from £0.3m or 1.4p per share a year ago. Revenue amounted to £0.2m (31 January 2014: £0.4m). These revenues are largely generated th
21-Apr-2015 03:09 PM

C4X Discovery schedules interims

C4X Discovery Holdings, a leader in rational drug discovery and design, will announce its results for the six months ended 31 January on 27 April. At 3:09pm: (LON:C4XD) C4x Discovery Holdings Plc Ord 1p share price was 0p at 81.25p Story provided by
10-Apr-2015 01:44 PM

C4XD changes registered office

C4X Discovery Holdings, a leader in rational drug discovery and design, has changed its registered office, with immediate effect to: Manchester One, 53 Portland Street, Manchester M1 3LD. At 1:44pm: (LON:C4XD) C4x Discovery Holdings Plc Ord 1p share pri
19-Jan-2015 07:59 AM

C4XD in new research agreement with Evotec

C4X Discovery Holdings, a leader in rational drug discovery and design, has entered into a research agreement with Evotec. Under the agreement C4XD's proprietary NMR-based technology and conformational design expertise will combine with Evotec&apos
18-Dec-2014 08:33 AM

C4X Discovery renews collaboration with Evotec

C4X Discovery, a leader in rational drug discovery and design, has extended its research collaboration agreement with Evotec. C4X chief executive Piers Morgan said "We are delighted to renew and extend our partnership with Evotec, a global leader in
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t